Injectable vs Oral GLP-1: Which Is Right for You?

Your doctor has recommended a GLP-1 medication. Now you're facing a follow-up question most people don't expect: inject it or swallow it? Injectables still hold the deepest clinical evidence base and the widest telehealth availability, but 2026 rewrote the oral side of this comparison. The Wegovy pill (oral semaglutide, approved December 2025) and Foundayo (orforglipron, approved April 2026) are both FDA-approved specifically for chronic weight management, joining Rybelsus (approved for type 2 diabetes). Each format still carries real trade-offs. This guide walks through injectable vs oral GLP-1 options so you can make an informed decision with your healthcare provider.

The injectable options

Weekly subcutaneous injections are the standard delivery method for GLP-1 medications. "Subcutaneous" means the injection goes into fat just under the skin, not into a vein or muscle. The needle is thin and short, and most patients report minimal discomfort after the first few weeks.

Brand-name injectables come in pre-filled auto-injector pens:

• Wegovy (semaglutide 2.4mg, Novo Nordisk) — FDA-approved for chronic weight management
• Ozempic (semaglutide 0.5mg–2mg, Novo Nordisk) — FDA-approved for type 2 diabetes, frequently prescribed off-label for weight loss
• Zepbound (tirzepatide, Eli Lilly) — FDA-approved for chronic weight management
• Mounjaro (tirzepatide, Eli Lilly) — FDA-approved for type 2 diabetes, prescribed off-label for weight loss

With a pre-filled pen, there's no measuring or loading. You dial the dose, press the pen against your skin, and click. Many patients describe the process as easier than they expected.

Compounded injectable semaglutide uses the same active ingredient as Wegovy and Ozempic but is not FDA-approved as a finished product. It's typically supplied as a multi-dose vial, which you draw into a syringe before injecting. This adds a step that requires some practice, though most patients get comfortable with it quickly.

The clinical evidence for injectable semaglutide is extensive. A major NEJM trial found that weekly subcutaneous semaglutide 2.4mg may reduce body weight by approximately 15% over 68 weeks in adults with obesity, compared to about 2.4% with placebo (Wilding et al., NEJM, 2021). No equivalent large-scale trials exist for injectable compounded formulations specifically.

The oral options

Until late 2025, "oral GLP-1" effectively meant Rybelsus or a compounded product. That changed quickly. There are now three FDA-approved oral GLP-1 medications, two of them approved specifically for weight management:

Wegovy pill (oral semaglutide 25mg, Novo Nordisk) was FDA-approved for chronic weight management on December 22, 2025, making it the first oral GLP-1 approved for weight loss (Novo Nordisk announcement). In the OASIS 4 trial, it produced approximately 13.6% mean weight loss over 64 weeks. Because it is still semaglutide, it carries the same fasting protocol as Rybelsus (below). Self-pay through NovoCare Pharmacy is $149/month.

Foundayo (orforglipron, Eli Lilly) was FDA-approved for chronic weight management on April 1, 2026 (FDA press release). Unlike the semaglutide pills, it is a non-peptide small molecule, so it can be taken any time of day, with or without food, and with no water restrictions. In the ATTAIN-1 trial, it produced approximately 11.1% mean weight loss at the highest dose (12.4% among trial completers). Cash pricing through LillyDirect runs $149–$349/month depending on dose. For a full head-to-head of the two new pills, see our Foundayo vs Wegovy pill comparison.

Rybelsus (oral semaglutide, Novo Nordisk) is FDA-approved for type 2 diabetes management, not for weight loss. Some providers prescribe it off-label for weight loss; its weight loss evidence base is more limited than either of the two newer pills.

The semaglutide pills (Rybelsus and Wegovy pill) require a strict fasting protocol: take the tablet first thing in the morning with no more than 4 ounces (120mL) of water, then wait at least 30 minutes before eating, drinking anything other than water, or taking other medications (Rybelsus prescribing information, FDA.gov). This protocol matters because oral semaglutide has low bioavailability (as low as 0.4% to 1% of the dose is absorbed), and the fasting window maximizes absorption. Skipping or shortening it can reduce how much of the medication actually reaches your bloodstream. That bioavailability gap is also why oral semaglutide doses are much higher than injectable ones: the Wegovy pill is 25mg daily while injectable Wegovy tops out at 2.4mg weekly. Foundayo, as a small molecule, does not have this absorption problem and carries no food or timing restrictions.

Oral compounded semaglutide was available through select telehealth providers until early 2026, when the FDA resolved the semaglutide shortage designation and most providers discontinued compounded oral offerings. As of mid-2026, availability through major telehealth platforms remains limited. Like compounded injectable semaglutide, oral compounded semaglutide contains the same active ingredient as brand-name products but is not FDA-approved as a finished product, and compounded oral formulations are even less studied than compounded injectables. With two FDA-approved weight loss pills now selling for $149/month through manufacturer-direct programs, the practical case for compounded oral semaglutide has narrowed considerably.

Head-to-head comparison

	Injectable GLP-1	Oral GLP-1
Efficacy evidence	Extensive: multiple large RCTs for brand-name injectables (~15% mean weight loss for Wegovy 2.4mg in STEP 1)	Strong for the new pills: ~13.6% for Wegovy pill (OASIS 4), ~11.1% for Foundayo (ATTAIN-1); more limited for off-label Rybelsus
Convenience	Weekly dosing; requires needle	Daily dosing; semaglutide pills require a strict fasting protocol, Foundayo has no food or timing restrictions
Cost	Brand-name: $299–$1,199/mo depending on provider and medication; compounded: $133–$299/mo	Wegovy pill: $149/mo self-pay (NovoCare); Foundayo: $149–$349/mo (LillyDirect); Rybelsus: ~$900+/mo list price
Availability	Widely available across telehealth providers	Growing quickly; major platforms began stocking Foundayo and the Wegovy pill in spring 2026
FDA approval	Brand-name: approved for weight loss or T2D; compounded: not approved as finished product	Wegovy pill and Foundayo: approved for chronic weight management; Rybelsus: T2D only; oral compounded: not FDA-approved as finished product
Dosing requirements	Inject once weekly; refrigerate medication	Daily; fasting protocol for semaglutide pills, any time of day for Foundayo

Which should you choose?

The honest answer used to be simple: injectables had all the evidence. That is no longer the whole story. Injectables still hold the largest evidence base and the highest published averages (about 15% mean weight loss for Wegovy 2.4mg, and roughly 21% for tirzepatide 15mg in SURMOUNT-1 (Jastreboff et al., NEJM, 2022)), but the Wegovy pill's roughly 13.6% OASIS 4 result puts the best oral option within striking distance. The choice now hinges less on efficacy and more on routine, cost, and which molecule you tolerate. The oral format is genuinely more convenient for many people, and convenience affects adherence.

On the needle concern: Many people who are hesitant about injections find the reality much easier than they imagined. GLP-1 auto-injector pens use a very fine, short needle. You inject into the fatty tissue of the abdomen or thigh — not a vein. It's not the same experience as a blood draw or IV. If needle anxiety is your main reason for considering oral, it may be worth trying an injectable first. Most providers can help you work through technique.

When oral makes sense: With two pills now FDA-approved specifically for weight management, oral is a first-class option rather than a fallback. It is worth discussing with your provider if you want to avoid needles entirely, if you travel often (no refrigeration), or if a daily pill fits your routine better than a weekly injection. If you cannot reliably follow the morning fasting protocol, Foundayo's no-restrictions dosing may fit better than the semaglutide pills. Patients already stable on an injectable should read the switching evidence first: our switching to Foundayo guide covers what the ATTAIN-MAINTAIN trial showed about moving from Wegovy or Zepbound to a pill.

On cost: The new pills are competitive with, and often cheaper than, injectables. Wegovy pill self-pay is $149/month through NovoCare Pharmacy, and Foundayo runs $149–$349/month through LillyDirect depending on dose. Rybelsus still lists at $900+/month, which makes it hard to justify for cash-pay weight loss now that purpose-approved alternatives cost a fraction of that. If an oral format is important to you, your provider can advise on current options.

Whatever format you're considering, all of these medications require a prescription. Consult your healthcare provider before starting any GLP-1 medication: they can factor in your medical history, medication tolerance, and specific weight loss goals.

Providers worth considering

Hims covers both formats: brand-name injectable Wegovy at $199/month plus a $149/month membership, and both new pills (Wegovy pill and Foundayo, each $149/month plus membership). Hims discontinued oral compounded semaglutide in Q1 2026 after striking a partnership with Novo Nordisk to sell brand-name GLP-1s instead. If you're comparing Hims with Ro, see our full Hims vs Ro breakdown.

For injectable-focused programs with strong clinical support, Found offers compounded injectable semaglutide at $169/month all-in (no separate membership fee), plus brand-name options and a full behavioral coaching program. And if you already have a prescription, the manufacturer-direct programs are the cheapest oral path: Foundayo through LillyDirect from $149/month, and the Wegovy pill through NovoCare Pharmacy at $149/month.